Financials
- Financial year
- 2025
- Total assets
- €758,621
- Profit
- €9,367
- Solvency
- 1.2%
PHARMA FOCH
ActiveSummary
The computed 12-month bankruptcy probability of PHARMA FOCH is 1.7% (moderate). The 2025 annual accounts show equity of €9,367 and a net result of €9,367. Its solvency ranks better than 14% of 12,434 sector peers (NACE 47, financial year 2025). The company has been active since 2024 and the Belgian Official Gazette contains no insolvency or warning signals.
Overview
Activity
Retail sale of pharmaceutical products
NACE 47730
1 site
Size
€758,621total assets 2025
- Staff
- 1.3 FTE
- Equity
- €9,367
- Profit
- €9,367
Turnover not published (abbreviated format)
Structure
Accounts filed 27 days late0 of 1 deed read
Why 54raises riskFounded in 2024Equity €9,367 (1.2% of total assets)lowers riskSize: 1.3 FTE, total assets €758,621Figures for financial year 2025 (filed 27-08-2026)Show the evidence
Checked score
Score 2025
54
/ 100
Fair
Probability in this band: 1.5% to 4.2%
Financially better than 27% of its sector peers (NACE 47, micro)
Financial strength
Weak
Solvency
26
equity 1.2% of total assets
Liquidity
7
short-term debt 98.8% · cash 5.2%
Profitability
70
return on assets 1.2%
Bankruptcy probability, 12 months
1.7%
Moderate
0%0.5%1.5%4%10%≥ 25%
About 2 in 100 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2025: 1.8%
01-2026: 1.8%● unchanged vs 12-2025
02-2026: 1.9%▲ +0.1 percentage points vs 01-2026
03-2026: 2.2%▲ +0.3 percentage points vs 02-2026
04-2026: 2.3%▲ +0.1 percentage points vs 03-2026
05-2026: 2.6%▲ +0.3 percentage points vs 04-2026
06-2026: 2.6%● unchanged vs 05-2026
07-2026: 2.8%▲ +0.2 percentage points vs 06-2026
08-2026: 2.9%▲ +0.1 percentage points vs 07-2026highest value
09-2026: 1.7%▼ -1.2 percentage points vs 08-2026
10-2026: 1.7%● unchanged vs 09-2026lowest value
Credit of up to €500 on 30-day terms is acceptable
Liquidity insufficient (current ratio 0.64, below 1; short-term debt: 98.8% and cash: 5.2% of total assets), and 98.8% of the assets are financed with debt and provisions.
How it is calculated
The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro): better than 20% on solvency, 8% on liquidity and 52% on profitability.
The bankruptcy probability was computed on 15-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).
Credit check for your own amount and term
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 14% of 12434 sector peers (2025).
NBB · sector comparisonPosition among 12434 sector peers
Solvency
better than 14%
← weakest
strongest →
neutral · Filed after the deadline
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 27-08-2026, 27 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 1 filingDeviation from the deadline
2025
27 days late
← before the deadline
after the deadline →
Searched, nothing found (1)
- Annual accounts filedfinancial year 2025 · abbreviated…
Key points
By topic
Timeline
- Events
- 1
- Since
- 2026
Company details
- Sites
- 1
- Legal form
- Private limited company
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Founded
- 26-11-2024
- Year ends
- 31-12
- Peppol
- Reachable for e-invoices
Go further with this company
How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark Is the workforce growing, and do people stay?Employer check
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.